Cardiol Therapeutics is a biotechnology company specializing in the research and commercial development of novel drug therapies utilizing proprietary drug-delivery systems.
Cardiol brings together a wealth of research and development experience, advanced manufacturing capabilities, and a Management team, Board of Directors, and Scientific Advisory Board comprising business and thought leaders with extensive industry experience and expertise in commercializing proprietary drugs.
We are leveraging our expertise in pharmaceutical cannabinoids to develop proprietary formulations for commercial development in three important medical markets, namely: commercializing a line of pharmaceutically-manufactured pure cannabidiol products in the growing market for medical cannabinoids, developing nanotechnologies designed to deliver cannabinoids and other anti-inflammatory drugs for the treatment of heart failure; and pursuing an immunotherapeutics program commencing with an innovative cancer immunotherapeutic in combination with cannabinoids for Glioblastoma Multiforme, a Fast Track eligible orphan indication.
Read more about Cardiol
David Elsley | President & CEO@Cardiol Therapeutics
Mr. David Elsley is a business leader with a proven track record of developing, financing and managing all aspects of corporate development in biotechnology and high-growth organizations.
In 1990, Mr. Elsley founded Vasogen Inc., a biotechnology company focused on the research and commercial development of novel therapeutics for the treatment of heart failure and other inflammatory conditions. Mr. Elsley assembled a team of management, directors and scientific advisors comprising industry professionals and thought leaders from North America and Europe.
Mr. Elsley managed and directed Vasogen’s growth from start-up to an organization employing over 250 people with operations and R&D programs in Canada, the United States and Europe. He established the research and development infrastructure, partnerships, manufacturing capability, and corporate quality systems necessary to advance two anti-inflammatory therapies from concept to completion of international multi-center pivotal phase III clinical trials involving 2,500 patients. Vasogen went public on the TSX and the Nasdaq, raising over $200 million to support corporate development and reached a market capitalization of over US$ 1 billion.
Mr. Elsley holds a Master of Business Administration from the Richard Ivey School of Business, University of Western Ontario.